CN101443006B - 作为cetp抑制剂的新颖的苄胺衍生物 - Google Patents

作为cetp抑制剂的新颖的苄胺衍生物 Download PDF

Info

Publication number
CN101443006B
CN101443006B CN200580048913XA CN200580048913A CN101443006B CN 101443006 B CN101443006 B CN 101443006B CN 200580048913X A CN200580048913X A CN 200580048913XA CN 200580048913 A CN200580048913 A CN 200580048913A CN 101443006 B CN101443006 B CN 101443006B
Authority
CN
China
Prior art keywords
carbon atoms
alkyl
independently
heteroaryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580048913XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101443006A (zh
Inventor
阿尼马·巴鲁阿
迪比恩杜·德
伊什·K·卡纳
西瓦拉姆·皮拉里塞蒂
桑塔努·梅特拉
克里斯托弗·W·亚历山大
詹纳帕利·斯里纳
因杜·戴杰
沙纳瓦斯·阿里昆珠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Reddy US Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy US Therapeutics Inc filed Critical Reddy US Therapeutics Inc
Priority to CN201210404509.3A priority Critical patent/CN103102303B/zh
Publication of CN101443006A publication Critical patent/CN101443006A/zh
Application granted granted Critical
Publication of CN101443006B publication Critical patent/CN101443006B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
CN200580048913XA 2004-12-31 2005-12-28 作为cetp抑制剂的新颖的苄胺衍生物 Expired - Fee Related CN101443006B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210404509.3A CN103102303B (zh) 2004-12-31 2005-12-28 作为cetp抑制剂的苄胺衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64079804P 2004-12-31 2004-12-31
US60/640,798 2004-12-31
PCT/US2005/047203 WO2006073973A2 (en) 2004-12-31 2005-12-28 Novel benzylamine derivatives as cetp inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210404509.3A Division CN103102303B (zh) 2004-12-31 2005-12-28 作为cetp抑制剂的苄胺衍生物

Publications (2)

Publication Number Publication Date
CN101443006A CN101443006A (zh) 2009-05-27
CN101443006B true CN101443006B (zh) 2012-10-10

Family

ID=36648035

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200580048913XA Expired - Fee Related CN101443006B (zh) 2004-12-31 2005-12-28 作为cetp抑制剂的新颖的苄胺衍生物
CN201210404509.3A Expired - Fee Related CN103102303B (zh) 2004-12-31 2005-12-28 作为cetp抑制剂的苄胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210404509.3A Expired - Fee Related CN103102303B (zh) 2004-12-31 2005-12-28 作为cetp抑制剂的苄胺衍生物

Country Status (10)

Country Link
US (2) US9040558B2 (enExample)
EP (1) EP1848430B1 (enExample)
JP (1) JP5096927B2 (enExample)
KR (1) KR101238525B1 (enExample)
CN (2) CN101443006B (enExample)
CA (1) CA2605214C (enExample)
DK (1) DK1848430T3 (enExample)
ES (2) ES2644450T3 (enExample)
MX (1) MX2007007919A (enExample)
WO (1) WO2006073973A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
CA2642130C (en) * 2005-12-28 2013-04-02 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
US20090075968A1 (en) * 2005-12-29 2009-03-19 Junichi Sakaki CETP inhibitors
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
KR101172120B1 (ko) 2006-05-10 2012-08-10 노파르티스 아게 Ｃｅｔｐ 억제제로서의 바이시클릭 유도체
GB0609268D0 (en) * 2006-05-10 2006-06-21 Novartis Ag Organic compounds
CN101443324A (zh) * 2006-05-11 2009-05-27 诺瓦提斯公司 作为cetp抑制剂的苄胺衍生物
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
BRPI0718809A2 (pt) * 2006-11-15 2013-12-03 Novartis Ag Compostos orgânicos
RU2009122504A (ru) * 2006-11-15 2010-12-20 Новартис АГ (CH) Гетероциклические производные в качестве ингибиторов белка сетр
WO2008097976A1 (en) * 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US7790737B2 (en) * 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
WO2008115442A1 (en) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibitors of cholesterol ester transfer protein
CN101679309B (zh) 2007-04-13 2012-02-29 兴和株式会社 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
CA2688187C (en) * 2007-05-07 2016-10-11 Merck & Co., Inc. Method of treament using fused aromatic compounds having anti-diabetic activity
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2598358T3 (es) * 2009-02-13 2017-01-27 Ucb Pharma, S.A. Derivados de quinolina como inhibidores de PI3K quinasa
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US9199967B2 (en) * 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
EP2760864B1 (en) * 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
US20140303198A1 (en) 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
JPWO2014017569A1 (ja) * 2012-07-26 2016-07-11 興和株式会社 血中ｌｄｌを低下させるための医薬
CA2891502A1 (en) * 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
JP2015054838A (ja) * 2013-09-12 2015-03-23 興和株式会社 血中ｌｄｌコレステロールを低下させる医薬
US10214502B2 (en) * 2016-10-04 2019-02-26 Mayo Foundation For Medical Education And Research Method of inhibiting apolipoprotein-E expression while increasing expression of at least one of LDL-receptor protein or AbcA1 protein comprising administering a small compound
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965643A (en) 1960-12-20 Derivatives of pyrazolo
CH273953A (de) * 1948-05-21 1951-03-15 Ciba Geigy Verfahren zur Herstellung von Aminen.
US2858309A (en) 1956-05-07 1958-10-28 Ciba Pharm Prod Inc New aminobenzene sulfonamide
US3546295A (en) 1968-08-01 1970-12-08 Exxon Research Engineering Co N-cycloalkyl anilines
US3713499A (en) * 1971-08-11 1973-01-30 Gulf Research Development Co Method and apparatus for treating drilling mud
IT8124760A0 (it) * 1980-10-29 1981-10-29 Nippon Kayaku Kk Derivati di 5,6,7,8-tetraidro-1,6-naftiridina e procedimento per la loro preparazione.
JPH01104052A (ja) 1987-06-12 1989-04-21 Yoshitomi Pharmaceut Ind Ltd ピリジン誘導体
EP0298666B1 (en) 1987-07-08 1993-08-11 American Home Products Corporation Spray dried ibuprofen compositions
US5089073A (en) * 1988-09-26 1992-02-18 W. R. Grace & Co.-Conn. High strength laminated film for chub packaging
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
GB8912784D0 (en) 1989-06-02 1989-07-19 Wyeth John & Brother Ltd Amines
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
HUT58270A (en) 1989-06-02 1992-02-28 Wyeth John & Brother Ltd Process for producing amine derivatives and pharmaceutical compositions containing them
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
ZA924659B (en) 1991-06-25 1993-03-31 Merck & Co Inc New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
TW225469B (enExample) 1991-11-12 1994-06-21 Nissan Kagakl Kogyo
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0585500A1 (en) 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
ATE161530T1 (de) * 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
AU5802894A (en) 1992-12-17 1994-07-04 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
MY131441A (en) 1992-12-29 2007-08-30 American Cyanamid Co Amidrazones and their use as insecticidal and acaricidal agents
AU682381B2 (en) 1993-08-12 1997-10-02 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
US5491152A (en) 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JPH0892224A (ja) 1994-09-16 1996-04-09 Kumiai Chem Ind Co Ltd ３，５−置換フェニルトリアゾール誘導体および殺虫、殺ダニ剤
JPH0892225A (ja) 1994-09-29 1996-04-09 Nissan Chem Ind Ltd トリアゾールグリコール酸アミド誘導体
CA2206315A1 (en) 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
JPH09235276A (ja) * 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
DE69726729T2 (de) 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998016508A2 (en) * 1996-10-02 1998-04-23 Trustees Of Boston University Synthesis of aromatic compounds by diels-alder reaction on solid support
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6008362A (en) 1997-06-16 1999-12-28 Commons; Thomas Joseph Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
WO1998057927A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
US5977170A (en) 1997-06-16 1999-11-02 American Home Products Corporation Elevation of HDL cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
AU7688398A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 2-{(aminothioxomethyl)-hydrazono}-2-arylethyl carbamates
AU7589598A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
WO1999055676A1 (en) * 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
US6121271A (en) 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE19845202A1 (de) 1998-10-01 2000-04-06 Wella Ag Haarwuchsmittel
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
PL350427A1 (en) 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
CN1247572C (zh) 1999-06-23 2006-03-29 辛根塔参与股份公司 制备硝基胍和硝基烯胺衍生物的方法
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6451823B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
WO2001045677A1 (en) 1999-12-20 2001-06-28 Kerkhof Nicholas J Process for producing nanometer particles by fluid bed spray-drying
DE19962300A1 (de) 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
WO2001060458A2 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20020019527A1 (en) * 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
JP3563070B2 (ja) 2000-07-17 2004-09-08 山之内製薬株式会社 経口吸収改善医薬組成物
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2004505942A (ja) * 2000-08-07 2004-02-26 ニューロゲン　コーポレイション Ｇａｂａａ受容体の配位子としての複素環式化合物
JP2002145778A (ja) * 2000-08-29 2002-05-22 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU2001294557A1 (en) 2000-09-11 2002-03-26 Merck And Co., Inc. Thrombin inhibitors
AU2002212598A1 (en) * 2000-09-19 2002-04-02 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
AU2002227269A1 (en) 2000-11-07 2002-06-03 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
WO2002055484A1 (en) * 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
UA74419C2 (uk) 2001-02-21 2005-12-15 Ен Пі Ес Фармасьютікалс, Інк. Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2004528378A (ja) 2001-05-08 2004-09-16 シエーリング アクチエンゲゼルシャフト Ｎ−オキシドアントラニルアミド誘導体と医薬製剤としての利用
JP2005500314A (ja) 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011935A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
DE60220049T2 (de) 2001-06-22 2007-08-30 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer
CA2448825C (en) 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP2003221376A (ja) * 2001-11-21 2003-08-05 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
JP2005522424A (ja) 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
JP2005528368A (ja) * 2002-03-29 2005-09-22 ニューロジェン・コーポレーション Ｃ５ａ受容体モジュレータである新規なアリールイミダゾール及び関連化合物。
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
SK2332004A3 (en) 2002-08-30 2004-12-01 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
GB0303683D0 (en) 2003-02-18 2003-03-19 Prolysis Ltd Antimicrobial agents
MXPA05009102A (es) 2003-02-28 2006-05-31 Bayer Pharmaceuticals Corp Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
PL378748A1 (pl) 2003-03-04 2006-05-15 Pfizer Products Inc. Zastosowanie selektywnych agonistów receptora EP2 w leczeniu
EP1638934B1 (en) 2003-06-11 2008-01-09 Eli Lilly And Company 3-aminopyrrolidines as inhibitors of monoamine uptake
CA2534371A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7276610B2 (en) 2003-08-27 2007-10-02 Janssen Pharaceutica, Nv Aryl piperidine amides
KR20060080214A (ko) 2003-09-26 2006-07-07 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
WO2005058831A1 (en) * 2003-12-12 2005-06-30 Syngenta Participations Ag Novel herbicides
WO2005058037A1 (en) * 2003-12-12 2005-06-30 Syngenta Participations Ag Picolinylpyrazoles as herbicides
ATE433984T1 (de) 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
MY139887A (en) 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EP1737811B1 (en) 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
AR053784A1 (es) 2004-11-23 2007-05-23 Pfizer Prod Inc Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas.
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
EP1893178A1 (en) 2005-05-31 2008-03-05 Pfizer Products Incorporated PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
CA2642130C (en) 2005-12-28 2013-04-02 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
CN103735515A (zh) 2006-02-09 2014-04-23 默沙东公司 Cetp抑制剂的聚合物制剂
KR101172120B1 (ko) 2006-05-10 2012-08-10 노파르티스 아게 Ｃｅｔｐ 억제제로서의 바이시클릭 유도체
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCULLEY，J.D..Some Amide Derivatives of Certain Aminomethylpyridines.<<Journal of the American Chemical Society>>.1958,第75卷3400-3403. *

Also Published As

Publication number Publication date
US9782407B2 (en) 2017-10-10
DK1848430T3 (da) 2017-11-06
KR101238525B1 (ko) 2013-02-28
KR20070102696A (ko) 2007-10-19
MX2007007919A (es) 2008-01-22
US9040558B2 (en) 2015-05-26
US20150216866A1 (en) 2015-08-06
CA2605214A1 (en) 2006-07-13
CN103102303A (zh) 2013-05-15
EP1848430A4 (en) 2011-12-28
HK1131055A1 (en) 2010-01-15
CA2605214C (en) 2016-07-12
EP1848430A2 (en) 2007-10-31
JP2008528447A (ja) 2008-07-31
ES2615340T3 (es) 2017-06-06
WO2006073973A3 (en) 2008-12-04
US20060178514A1 (en) 2006-08-10
ES2644450T3 (es) 2017-11-29
CN101443006A (zh) 2009-05-27
CN103102303B (zh) 2015-10-28
WO2006073973A2 (en) 2006-07-13
JP5096927B2 (ja) 2012-12-12
EP1848430B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CN101443006B (zh) 作为cetp抑制剂的新颖的苄胺衍生物
US9765030B2 (en) Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
KR102680164B1 (ko) Rock 억제제로서의 페닐아세트아미드
JP6434968B2 (ja) Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
RU2615130C2 (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
AU2006289838B2 (en) Heterocyclic compound, and production process and use thereof
AU2012272895B2 (en) TRPM8 antagonists and their use in treatments
CS249533B2 (en) Method of quinolones&#39;s derivatives production
IL264186B1 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
TW200817411A (en) Pyrimidine derivative as PI3 inhibitor and use thereof
CA2642130C (en) Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
US20200048223A1 (en) Wnt signaling pathway inhibitors and therapeutic applications thereof
CN101501035A (zh) 作为p13k抑制剂的嘧啶衍生物及其用途
US9260441B2 (en) Heteroaryl compounds with cyclic bridging unit
HK1131055B (en) Novel benzylamine derivatives as cetp inhibitors
JP2025523256A (ja) ヘテロアリール誘導体化合物およびその用途
KR20250043288A (ko) 티아졸 유도체 화합물을 포함하는 폐섬유화증 치료용 조성물
KR20250043287A (ko) 티아졸 유도체 화합물을 포함하는 장섬유화증 치료용 조성물
NZ569415A (en) Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131055

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Baruah Anima

Inventor after: De Dibyendu

Inventor after: Khanna Ish Kumar

Inventor after: Pillarisetti Sivaram

Inventor after: Maitra Santanu

Inventor after: Alexander Christopher W

Inventor after: Sreenu Jennepalli

Inventor after: Dager Indu

Inventor after: Shanawaz Arequn Juliet

Inventor before: Baruah Anima

Inventor before: De Dibyendu

Inventor before: Khanna Ish Kumar

Inventor before: Pillarisetti Sivaram

Inventor before: Maitra Santanu

Inventor before: Alexander Christopher W

Inventor before: Sreenu Jennepalli

Inventor before: Dager Indu

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: BARUAH ANIMA DE DIBYENDU KHANNA ISH KUMAR PILLARISETTI SIVARAM MAITRA SANTANU ALEXANDER CHRISTOPHER W. SREENU JENNEPALLI DAGER INDU TO: BARUAH ANIMA DE DIBYENDU KHANNA ISH KUMAR PILLARISETTI SIVARAM MAITRA SANTANU ALEXANDER CHRISTOPHER W. SREENU JENNEPALLI DAGER INDU SHANAWASI ALIKUNZHU

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: REDDYS LAB LTD.

Free format text: FORMER OWNER: REDDY US THERAPEUTICS INC.

Effective date: 20130217

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130217

Address after: Andhra Pradesh

Patentee after: Reddys Lab Ltd Dr.

Address before: Georgia, USA

Patentee before: Reddy US Therapeutics Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131055

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121010

Termination date: 20181228

CF01 Termination of patent right due to non-payment of annual fee